ClinicalTrials.gg
CompletedNCT01766024Updated May 4, 2016Results posted

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

A Phase 1 interventional study of Interferon beta-1a in Healthy, sponsored by Biocad. Completed at 1 site in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-04.

Sponsored by Biocad · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and tolerability of BCD-033 (interferon beta-1a manufactured by CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.A.., Italy) in healthy volunteers. The purpose of the study is to demonstrate the non-inferiority of pharmacokinetics, pharmacodynamics and tolerability parameters after single subcutaneous injection. Each dtug will be administered to each volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least 14 days.

Read the detailed description

Each dtug (BCD-033 and Rebif) will be administered to each volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least 14 days.

02

Conditions studied

  • Healthy

Keywords

  • interferon beta-1a
  • pharmacokinetics
  • pharmacodynamics
  • volunteers
03

In context

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written ;
  • Male gender;
  • Age 18 - 45 years inclusive;
  • (BMI) (18,5 - 24,99 kg/m2);
  • Healthy condition proven by the volunteer's history, global assessment and laboratory analysis results:
  • Absence in past medical history and at screening of dysfunctions of circulatory, respiratory, nervous, hematopoietic, endocrine and digestive systems, liver and kidneys;
  • Haematology and biochemistry tests, urinalysis and thyroid hormone analysis results are within normal limits according to standards of the study site. Screening laboratory analyses should be performed not more than 14 days before volunteer's inclusion in the study;
  • Hemodynamic parameters are within normal limits: systolic blood pressure - from 100 to 139 mmHg, diastolic blood pressure - from 60 to 90 mmHg, heart rate - from 50 to 90 bpm;
  • Absence of history of chronic infection (tuberculosis) and chronic inflammation;
  • Absence of , and C virus, syphilis;
  • Absence of acute infections within 4 weeks before inclusion in the study;
  • Absence of psychiatric disorders and other conditions that can interfere with volunteer's ability to follow the study protocol, including depression;
  • Well-being (in volunteer's opinion) within 30 days before participation in the study;
  • Absence of history of systematic alcohol and drug abuse;
  • Ability of the volunteer, in investigator's opinion, to follow the study protocol procedures and requirements;
  • Willingness of volunteers and their sexual partners of to use reliable methods starting from 2 weeks before inclusion into the study and until 4 weeks after receiving the last dose of the products. This criterion is not applicable to patients who underwent surgical sterilization. Reliable contraceptive measures include one barrier method in combination with one of the following methods: spermicides, intrauterine device or oral contraceptives used by participant's partner;
  • Consent to avoid alcohol intake within 24 hours before and 8 days after each administration of the test or reference drugs;
  • Consent to avoid grapefruit juice (or other products containing grapefruit) intake within 72 hours before and 8 days after each administration of the study or reference drugs.

Exclusion criteria

Exclusion Criteria:

  • Previous use of IFN-β1-containing medications at any time before inclusion;
  • History of serious allergic reactions (anaphylaxis or multiple allergy);
  • Known allergy or intolerance to interferons or any other components of study or reference drugs;
  • Major surgery within 30 days before screening;
  • Impossibility to install venous catheter for blood sampling (e.g. because of skin disorders at the sites of venipuncture);
  • Diseases or other conditions that can interfere with the drugs pharmacokinetics (e.g. chronic liver, kidney, blood, circulatory system, lung or neuroendocrine diseases, including diabetes mellitus and others);
  • History of epileptic seizures;
  • Regular oral or parenteral use of any medications including over-the-counter drugs, vitamins and nutritional additives within less than 2 weeks before inclusion in the study;
  • Intake of medications, including over-the-counter drugs and biologically active additives that can influence hemodynamics, liver function etc. (barbiturates, omeprazole, cimetidine etc.) within less than 30 days before inclusion in the study;
  • Intake of medications that influence immune status (cytokines and their inductors, etc.) within less than 30 days before participation in the study;
  • Smoking more than 10 cigarettes per day;
  • Subjects who consume more than 10 units of alcohol per week or who have history of alcohol abuse or evidence of drug/chemical abuse (one unit of alcohol equals ½ l [500 ml] of beer, one glass [200 ml] of wine or l shot glass [50 ml] of spirits);
  • Donation of 450 ml and more of blood or plasma within 2 months before inclusion in the study;
  • Participation in other clinical studies within less than 1 month before inclusion in the study or simultaneous participation in another clinical study;
  • Previous participation in this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    BCD-033 → Rebif

    Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.

    Drug: Interferon beta-1a

  • Experimental
    Rebif → BCD-033

    Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.

    Drug: Interferon beta-1a

Interventions

  • Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.

    Also known as: BCD-033, Rebif

06

What researchers measure

Primary outcomes

  1. Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞) Respectively)

    Primary outcome measure for pharmacokinetics analysis. Blood samples were taken before the injection, then after 15 min, 30 min, 45 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours and 48 hours.

    Time frame: 0 to 48 hours post-dose

  2. Cmax of Interferon Beta-1a

    Primary outcome measure for pharmacokinetics analysis Blood samples were taken before the injection, then after 15 min, 30 min, 45 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours and 48 hours.

    Time frame: 0 to 48 hours post-dose

  3. AUC(0-168) and AUC(0-∞) of Neopterin and MxA Protein

    Primary outcome measure for pharmacodynamics analysis. Blood samples were taken before the injection, then after 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours.

    Time frame: 0 to 168 hours post-dose

Secondary outcomes

  1. Тmax of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.

    Secondary outcome measure for pharmacokinetics analysis

    Time frame: 0 to 48 hours post-dose

  2. Т½ of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.

    Secondary outcome measure for pharmacokinetics analysis

    Time frame: 0 to 48 hours post-dose

  3. Кel of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.

    Secondary outcome measure for pharmacokinetics analysis

    Time frame: 0 to 48 hours post-dose

  4. Cl of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.

    Secondary outcome measure for pharmacokinetics analysis

    Time frame: 0 to 48 hours post-dose

  5. Cmax of Neopterin and MxA Protein Blood Samples Were Taken Before the Injection, Then After 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 Hours.

    Secondary outcome measure for pharmacodynamics analysis

    Time frame: 0 to 168 hours post-dose

  6. Tmax of Neopterin and MxA Protein

    Secondary outcome measure for pharmacodynamics analysis

    Time frame: 0 to 168 hours post-dose

  7. Adverse Event (AE) and Serious Adverse Event (SAE) Incidence

    Secondary outcome measure for safety assessment

    Time frame: up to Day 43

  8. AE of Garde 3-4 Incidence

    Secondary outcome measure for safety assessment

    Time frame: up to Day 43

  9. Local Reaction Incidence

    Secondary outcome measure for tolerability assessment

    Time frame: up to Day 43

  10. Study Withdrawal Rate Due to AE

    Secondary outcome measure for safety assessment

    Time frame: up to Day 43

07

Results

Posted Feb 16, 2015

Participant flow

Participant flow — Overall Study
MilestoneBCD-033 → RebifRebif → BCD-033
Started1616
Completed1616
Not completed00

Outcome measures

PrimaryArea Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞) Respectively)

Primary outcome measure for pharmacokinetics analysis. Blood samples were taken before the injection, then after 15 min, 30 min, 45 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours and 48 hours.

Time frame:
0 to 48 hours post-dose
Reported as:
Median · (pg/ml)•h
Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞) Respectively)
(pg/ml)•hBCD-033Rebif
Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞) Respectively)6318.3 (5368.4 to 7484.9)6807.9 (5714.9 to 8920.1)
PrimaryCmax of Interferon Beta-1a

Primary outcome measure for pharmacokinetics analysis Blood samples were taken before the injection, then after 15 min, 30 min, 45 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours and 48 hours.

Time frame:
0 to 48 hours post-dose
Reported as:
Median · pg/ml
Cmax of Interferon Beta-1a
pg/mlBCD-033Rebif
Cmax of Interferon Beta-1a104.9 (80.2 to 123.4)102.4 (83.6 to 148.6)
PrimaryAUC(0-168) and AUC(0-∞) of Neopterin and MxA Protein

Primary outcome measure for pharmacodynamics analysis. Blood samples were taken before the injection, then after 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours.

Time frame:
0 to 168 hours post-dose
Reported as:
Median · (ng/ml)*h
AUC(0-168) and AUC(0-∞) of Neopterin and MxA Protein
(ng/ml)*hBCD-033Rebif
neopterin552.7 (458.1 to 661.6)537.6 (392.6 to 680.1)
MxA protein2444.2 (2005.5 to 3011.2)2131.2 (1728.0 to 3245.0)
SecondaryТmax of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.

Secondary outcome measure for pharmacokinetics analysis

Time frame:
0 to 48 hours post-dose

Results for this outcome have not been posted.

SecondaryТ½ of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.

Secondary outcome measure for pharmacokinetics analysis

Time frame:
0 to 48 hours post-dose

Results for this outcome have not been posted.

SecondaryКel of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.

Secondary outcome measure for pharmacokinetics analysis

Time frame:
0 to 48 hours post-dose

Results for this outcome have not been posted.

SecondaryCl of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.

Secondary outcome measure for pharmacokinetics analysis

Time frame:
0 to 48 hours post-dose

Results for this outcome have not been posted.

SecondaryCmax of Neopterin and MxA Protein Blood Samples Were Taken Before the Injection, Then After 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 Hours.

Secondary outcome measure for pharmacodynamics analysis

Time frame:
0 to 168 hours post-dose

Results for this outcome have not been posted.

SecondaryTmax of Neopterin and MxA Protein

Secondary outcome measure for pharmacodynamics analysis

Time frame:
0 to 168 hours post-dose

Results for this outcome have not been posted.

SecondaryAdverse Event (AE) and Serious Adverse Event (SAE) Incidence

Secondary outcome measure for safety assessment

Time frame:
up to Day 43

Results for this outcome have not been posted.

SecondaryAE of Garde 3-4 Incidence

Secondary outcome measure for safety assessment

Time frame:
up to Day 43

Results for this outcome have not been posted.

SecondaryLocal Reaction Incidence

Secondary outcome measure for tolerability assessment

Time frame:
up to Day 43

Results for this outcome have not been posted.

SecondaryStudy Withdrawal Rate Due to AE

Secondary outcome measure for safety assessment

Time frame:
up to Day 43

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCD-033—0/32 (0%)32/32 (100%)
Rebif—0/32 (0%)32/32 (100%)
Most frequent other events
Most frequent other events
EventBCD-033Rebif
Flu-like syndromGeneral disorders32/3232/32
Local reactionsGeneral disorders13/3215/32

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BCD-033 → RebifRebif → BCD-033Total
<=18 years000
Between 18 and 65 years161632
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)BCD-033 → RebifRebif → BCD-033Total
Female000
Male161632
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BCD-033 → RebifRebif → BCD-033Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White161632
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)BCD-033 → RebifRebif → BCD-033Total
Russian Federation161632
08

Study locations

1 site
  • City Mariin Hospital
    St. Petersburg, 194104, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2013
First posted
Jan 11, 2013
Start
Feb 2013
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Feb 16, 2015
Last update
May 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01766024
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Jan 11, 2013
Start date
Feb 2013
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Feb 16, 2015
Last update
May 4, 2016

Study contacts

Ivan Sardaryan, PhD
principal investigator · City Mariin Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion